A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand
Keywords:
COVID-19 pandemic, thalassemias, iron overload, associated co-morbidities, clinical outcome, update.Abstract
A review of the literature on COVID-19 pandemic in patients with thalassemias is presented. Globally, the prevalence of COVID-19 among β-thalassemia patients seems to be lower than in general population; associated co-morbidities aggravated the severity of COVID- 19, leading to a poorer prognosis, irrespective of age. A multicenter registry will enhance the understanding of COVID-19 in these patients and will lead to more evidence-based management recommendations.
References
Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. Published 2010 May 21. doi:10.1186/1750-1172-5-11.
De Sanctis V, Kattamis C, Canatan D, et al. β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. Mediterr J Hematol Infect Dis. 2017;9(1):e2017018. Published 2017 Feb 20. doi:10.4084/MJHID.2017.018.
Cappellini MD, Motta I. New therapeutic targets in transfusion-dependent and -independent thalassemia. Hematology Am Soc Hematol Educ Program. 2017;1:278‐283.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease
(COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239–1242.
Eleftheriou A. Thalassaemia & Sickle Cell Disease: Classification of Risk Groups & Other Considerations
Guidance for Patients, Parents & Healthcare Professionals. 14 May 2020.
Canatan D, De Sanctis V. The medical concerns of patients with thalassemias at the time of COVID-19 outbreak: The personal experience and the international recommendations. Acta Biomed. 2020;91:218‐221.
Karimi M, De Sanctis V. Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category?. Acta Biomed. 2020;91:50‐56.
Motta I, De Amicis MM, Pinto VM, et al. SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience [published online ahead of print, 2020 Apr 20]. Am J Hematol. 2020;10.1002/ ajh.25840. doi:10.1002/ajh.25840.
Karimi M, Haghpanah S, Azarkeivan A, et al. Prevalence and Mortality due to Outbreak of Novel Coronavirus Disease (COVID-19) in β-Thalassemias: The Nationwide Iranian Experience [published online ahead of print, 2020 Jun 2]. Br J Haematol. 2020;10.1111/bjh.16911.
De SanctisV, Canatan D, Vives Corrons JL, et al. Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study. Mediterr J Hematol Infect Dis. 2020 (accepted for publication).
Marhaeni W, Wijaya AB, Kusumaningtyas P, Mapianto RS. Thalassemic Child Presenting with Anosmia due to COVID-19 [published online ahead of print, 2020 Jun 9]. Indian J Pediatr. 2020;1. doi:10.1007/ s12098-020-03370-4.
Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology. 2020;58:194–196.
Mao L, Wang M, Chen S, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. (February 24, 2020). Available at SSRN http://dx.doi.org/10.2139/ssrn.3544840.
Goncalves S, Goldstein BJ. Pathophysiology of olfactory disorders and potential treatment strategies. Curr Otorhinolaryngol Rep. 2016;4:115–121.
Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. Published 2020 Feb 24. doi:10.1038/s41368-020-0074-x.
Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients. J Korean Med Sci. 2020;35(18):e174. Published 2020 May 11. doi:10.3346/jkms.2020.35.e174.
Thalassemia International Federation .The COVID–19 pandemic and haemoglobin disorders. A contribution of Thalassaemia International Federation to its global patients’ community. https://thalassaemia.org.cy/publications/tif-publications/a-tif-proposed-haemoglobinopathy-patient-pathway-during-the-covid-19-pandemic-2.
Vives Corrons JL, De Sanctis V. Rare Anaemias, Sickle-Cell Disease and COVID-19. Acta Biomed. 2020;91(2):216‐217. Published 2020 May 11. doi:10.23750/abm.v91i2.9532.
Taher AT, Bou-Fakhredin R, Kreidieh F, et al. Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations [published online ahead of print, 2020 May 11]. Am J Hematol. 2020;10.1002/ajh.25857.
Chowdhury SF, Anwar S. Management of Hemoglobin Disorders During the COVID-19 Pandemic. Front. Med.2020;7:306.doi:10.3389/fmed.2020.00306.
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
